极氪汽车公布：2025年12月交付新车30267台，月销首次超过3万台，创历史新高，同比增长11.3%，环 比增长4.9%。2025全年极氪总计交付224133台，较2024年实现同比增长，稳居中国高端豪华新能源汽 车市场头部阵营，全球累计交付近65万台。其中，旗舰SUV极氪9X作为年度现象级爆款，继11月成为 50万以上大型 SUV销冠后，12月交付首破10000台。009持续引领40万以上豪华MPV市场，其他主力车 型如001、7X也成为各细分市场标杆。 据悉，除国内市场外，极氪还积极开拓全球市场，目前已进入50多个国家和地区，全球门店超640家， 在中国香港、东南亚、澳洲、巴西、埃及等多个地区展现出强大的市场号召力。有行业人士认为，极氪 回归一个吉利后，在深厚的体系力及技术力支撑下，专注豪华市场，已成为中国豪华品牌向上突破、走 向全球的典范。 ...

Core Viewpoint - Tesla is facing significant challenges in its key markets, including China, Europe, and North America, with declining sales and market share, indicating a loss of its once-dominant position in the electric vehicle industry [1][16]. Group 1: Market Challenges - In China, Tesla's sales are being heavily impacted by the rise of local brands that are aggressively competing in the same price segments, particularly in the 200,000 to 300,000 RMB range, which is crucial for Tesla's Model 3 and Model Y [2][4]. - In Europe, Tesla's total sales in the first four months of 2025 dropped to 62,000 units, a nearly 40% year-on-year decrease, with market share falling from 1.8% to 1% [1]. - In North America, Tesla's sales also saw a rare decline of nearly 20% year-on-year in April 2025, indicating a broader trend of losing market dominance to traditional automakers transitioning to electric vehicles [1]. Group 2: Product Challenges - Tesla's product lineup is perceived as outdated, with the Model 3 and Model Y being the only significant offerings, leading to a lack of fresh appeal among consumers [6][9]. - The anticipated launch of the "Model 2" has been delayed, preventing Tesla from competing effectively in the lower price segments where competitors like BYD are gaining traction [5][17]. - The design language of Tesla's vehicles, once revolutionary, is now seen as simplistic and outdated compared to the rapid iterations of competitors [7][9]. Group 3: Consumer Perception - Tesla's brand image as a technological leader is diminishing as local competitors like Huawei and Xpeng have established strong reputations for their advanced technologies [10][12]. - Negative public relations incidents, such as the "brake failure" controversy and issues at the Shanghai Auto Show, have contributed to a decline in consumer trust [12]. Group 4: Strategic Challenges - The rollout of Tesla's Full Self-Driving (FSD) technology in China has faced significant hurdles, limiting its potential as a competitive advantage [13][15]. - The competitive landscape has shifted, with local brands having already educated the market and established data advantages, making it difficult for Tesla to regain its former status [15][17]. - Tesla must adopt a more localized approach and improve communication with global markets to rebuild brand trust and relevance [17].

Summary of Erasca (ERAS) FY Conference Call - June 10, 2025 Company Overview - **Company Name**: Erasca (ERAS) - **Mission**: Focused on eradicating RAS-driven cancers, which are mutated in approximately 30% to 50% of all diagnosed cancers annually [3][4] Key Programs - **Current Pipeline**: - **ERAS 15**: A pan RAS molecular glue, recently cleared IND [4][11] - **ERAS 4,001**: A pan KRAS inhibitor, also recently cleared IND [4][11] - **ERAS 12**: A bispecific antibody targeting EGFR, in earlier stages [5] Market Opportunity - **Unmet Need**: Millions of patients diagnosed annually with RAS mutant tumors, with 2.2 million for KRAS and 2.7 million including H and NRAS [7][38] - **Competitive Landscape**: - ERAS 15 has one main competitor, Revolution Medicine's RMC-6,236, but the space is relatively uncrowded due to chemistry and IP challenges [8][10] - The pan KRAS market is more competitive, but ERAS believes their program has a strong profile [8][10] Clinical Development Timeline - **IND Clearances**: Both ERAS 15 and 4,001 received IND clearances in May 2025, ahead of guidance [11][12] - **Phase I Data**: Expected in calendar year 2026 for both programs [12][37] - **Enrollment**: No concerns regarding enrollment due to high unmet need and interest from leading centers [38][39] Preclinical Data Highlights - **Binding Affinity**: ERAS 15 shows 8 to 20 times higher binding affinity to cyclophilin A compared to RMC-6,236 [14] - **In Vitro Potency**: 4 to 5 times greater potency than RMC-6,236 [15] - **Dosing**: Anticipated human dose for ERAS 15 to be about one-tenth of the comparator's dose, potentially leading to better tolerability [18][29] Safety and Efficacy Considerations - **Toxicity Monitoring**: Accumulation of the drug will be monitored, but no major concerns anticipated regarding drug-induced liver injury due to different binding mechanisms [30][31] - **Combination Therapies**: Plans to explore combinations with standard care agents, including cetuximab and PD-1 inhibitors [49][50] Financial Overview - **Licensing Agreements**: - ERAS 15: Upfront payment of $12.5 million, total deal value around $189 million [53] - ERAS 4,001: Upfront payment of $10 million, total deal value around $170 million [55] - **Cash Runway**: Extended guidance to the second half of 2028, providing over three years of cash [67] Strategic Focus - **Reprioritization**: Shifted focus from a pan RAF inhibitor (neparafenib) to RAS programs due to higher unmet needs and potential [59] - **Partnership Opportunities**: Open to finding strategic partners for neparafenib, with no rush to finalize a deal [63] Investor Sentiment - **Positive Feedback**: Investors have responded favorably to the strategic focus on RAS assets and extended cash runway [66][68] Conclusion - **Future Outlook**: Erasca is well-positioned with a strong pipeline and ample cash runway to advance its RAS programs, aiming to address significant unmet needs in oncology [73]